| scholarly article | Q13442814 |
| P2093 | author name string | Yun Li | |
| David Lawrence | |||
| Annie Yang | |||
| Yanmei Lu | |||
| Sarajane Ross | |||
| Dylan Daniel | |||
| Avi Ashkenazi | |||
| Rienk Offringa | |||
| Scot Marsters | |||
| Jean-Michel Vernes | |||
| Klara Totpal | |||
| Nicholas S Wilson | |||
| Sharon Yee | |||
| Gloria Meng | |||
| Robert Pitti | |||
| Becky Yang | |||
| Sarah Hymowitz | |||
| Stefanie Loeser | |||
| Bob Kelley | |||
| Cam Adams | |||
| P2860 | cites work | Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors | Q36342757 |
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 101-113 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells | |
| P478 | volume | 19 |
| Q56334293 | A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer |
| Q42445183 | A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies |
| Q41671765 | A potent human neutralizing antibody Fc-dependently reduces established HBV infections |
| Q35936863 | Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma |
| Q37125759 | Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies |
| Q35945079 | Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer |
| Q27694769 | Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies |
| Q38754659 | Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro. |
| Q42729928 | Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking |
| Q35889630 | Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties |
| Q91808144 | Antibody Structure and Function: The Basis for Engineering Therapeutics |
| Q34370627 | Antibody therapeutics in cancer. |
| Q37994278 | Antibody-based immunotherapy of cancer |
| Q38103583 | Antibody-based therapy in colorectal cancer |
| Q41712371 | Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma |
| Q37353182 | Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo |
| Q38923528 | Antitumor activity of an anti-CD98 antibody. |
| Q24301064 | Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity |
| Q36079365 | Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement |
| Q26852287 | Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells |
| Q35954775 | Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. |
| Q48012057 | Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions |
| Q39063100 | CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells |
| Q39028796 | CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants |
| Q50125936 | Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies |
| Q27853200 | Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma |
| Q36512532 | Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. |
| Q36762882 | Clinical targeting of the TNF and TNFR superfamilies |
| Q38645178 | Combination cancer immunotherapies tailored to the tumour microenvironment |
| Q39192585 | Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties |
| Q52342639 | Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. |
| Q34978570 | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. |
| Q89819273 | Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism |
| Q33627385 | DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo. |
| Q26865568 | Death receptor-ligand systems in cancer, cell death, and inflammation |
| Q37273700 | Design of CD40 agonists and their use in growing B cells for cancer immunotherapy |
| Q35556794 | Development of an Fn14 agonistic antibody as an anti-tumor agent |
| Q38728582 | Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform |
| Q38823727 | Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. |
| Q89435524 | Effects of an FcγRIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies |
| Q35600313 | Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine |
| Q38268896 | Emerging biomarkers in head and neck cancer in the era of genomics. |
| Q42718215 | Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells |
| Q27678516 | Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131 |
| Q35590091 | Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. |
| Q37114367 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? |
| Q37021699 | Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance |
| Q36546646 | Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. |
| Q40560816 | Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. |
| Q38239286 | Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer |
| Q37998314 | Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond |
| Q38131758 | Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies |
| Q49847008 | FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody. |
| Q38239285 | FcγRIIB as a key determinant of agonistic antibody efficacy |
| Q37990547 | FcγRIIB: a modulator of cell activation and humoral tolerance. |
| Q38094625 | FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. |
| Q39175137 | Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity |
| Q42280832 | Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization |
| Q28656460 | Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies |
| Q41328292 | Gene expression of NOX family members and their clinical significance in hepatocellular carcinoma. |
| Q90089266 | Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models |
| Q27027460 | Getting TRAIL back on track for cancer therapy |
| Q35931441 | H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. |
| Q38770814 | Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities |
| Q94547635 | How to select IgG subclasses in developing anti-tumor therapeutic antibodies |
| Q92756792 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy |
| Q41483641 | Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo |
| Q39279968 | Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. |
| Q37963914 | In vitro cytokine release assays: reducing the risk of adverse events in man. |
| Q26772080 | Influence of immunoglobulin isotype on therapeutic antibody function |
| Q38275268 | Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies |
| Q38931186 | Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors |
| Q38066195 | Mechanisms of action of CD20 antibodies |
| Q60949513 | Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis |
| Q42660162 | Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy |
| Q91716512 | Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation |
| Q30423909 | Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? |
| Q38931192 | Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction |
| Q92797801 | New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models |
| Q56890819 | New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy |
| Q46527001 | Next generation antibody drugs: pursuit of the 'high-hanging fruit'. |
| Q92344226 | Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox |
| Q44805706 | OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy |
| Q56908538 | Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity |
| Q36689755 | Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells |
| Q26768160 | Onto better TRAILs for cancer treatment |
| Q64052040 | Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity |
| Q26796270 | Principles of antibody-mediated TNF receptor activation |
| Q37624164 | Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy |
| Q38752906 | Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB. |
| Q55340117 | Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. |
| Q38782706 | Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies |
| Q41855863 | Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer |
| Q56891909 | Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens |
| Q58547260 | Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism |
| Q51760860 | Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. |
| Q30549646 | Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells |
| Q64066922 | TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity |
| Q42623198 | TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial |
| Q34557885 | TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells |
| Q37889112 | TRAIL-mediated signaling in prostate, bladder and renal cancer |
| Q92757990 | TRAILblazing Strategies for Cancer Treatment |
| Q33872482 | Targeting CD137 enhances the efficacy of cetuximab. |
| Q38500801 | Targeting TRAIL in the treatment of cancer: new developments. |
| Q27009348 | Targeting and utilizing primary tumors as live vaccines: changing strategies |
| Q55012569 | Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. |
| Q64102267 | Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB |
| Q38340808 | Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions |
| Q92475952 | Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members |
| Q36580632 | The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl |
| Q39674450 | The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking |
| Q37262995 | The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. |
| Q56891562 | The promise and challenges of immune agonist antibody development in cancer |
| Q37995919 | The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. |
| Q37981038 | The secret ally: immunostimulation by anticancer drugs |
| Q37962655 | The therapeutic potential of TRAIL receptor signalling in cancer cells. |
| Q42372842 | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? |
| Q37114025 | Therapeutic applications of TRAIL receptor agonists in cancer and beyond |
| Q38749841 | Therapeutic targeting of CD70 and CD27. |
| Q55268648 | Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. |
| Q26991899 | Translating basic mechanisms of IgG effector activity into next generation cancer therapies |
| Q47325431 | Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications |
| Q36038408 | Trial Watch: Monoclonal antibodies in cancer therapy |
| Q42091109 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. |
| Q38974641 | Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation |
| Q38232105 | Type I and type II Fc receptors regulate innate and adaptive immunity |
| Q37547365 | Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag |
| Q36347307 | Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation |
| Q38615353 | bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. |
| Q37492231 | hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma |
Search more.